Skip to content
OpenCapital
Get started

QuidelOrtho Corporation QDEL Cash & Equivalents

Cash & Equivalents at other companies

Abbott logo
AbbottABT
$6.8B+4.1%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$509M-2.7%
Danaher logo
DanaherDHR
$5.7B+186%
Revvity logo
RevvityRVTY
$861.47M-24.3%
Quest Diagnostics logo
Quest DiagnosticsDGX
$393M+109%
Agilent Technologies logo
Agilent TechnologiesA
$1.81B+21.5%

Other financials

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation

See full
Market cap$832.61M-56.1%
Enterprise value$3.8B-22.0%
P/S0.3×-0.4×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp
FCF margin13.8%—

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is QuidelOrtho Corporation's cash & equivalents?
QuidelOrtho Corporation (QDEL) reported cash & equivalents of $140.4M in Q1 2026.
How has QuidelOrtho Corporation's cash & equivalents changed year-over-year?
QuidelOrtho Corporation's cash & equivalents increased by 10.4% year-over-year, from $127.2M to $140.4M.
What is the long-term trend for QuidelOrtho Corporation's cash & equivalents?
Over 4 years (2021 to 2025), QuidelOrtho Corporation's cash & equivalents has grown at a -32.2% compound annual growth rate (CAGR), from $802.8M to $169.8M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.